Vincerx Pharma (VINC) News Today $0.30 0.00 (0.00%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Vincerx Pharma Inc: Strategic Advancements and Promising Pipeline Highlight Buy RatingNovember 14 at 2:05 PM | markets.businessinsider.comVincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2024 Financial ResultsNovember 13 at 4:24 AM | finanznachrichten.deVincerx Pharma Reports Q3 2024 Financial ResultsNovember 13 at 4:24 AM | markets.businessinsider.comVincerx Pharma: A Strong Buy on Promising VIP943 Clinical Results and Strategic FocusOctober 9, 2024 | markets.businessinsider.comPenny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer CandidatesOctober 8, 2024 | benzinga.comVincerx Reports Positive Initial Clinical Data From VIP943 Phase 1 Dose-Escalation StudyOctober 8, 2024 | markets.businessinsider.comVincerx Pharma (NASDAQ:VINC) Stock, Insider Trading ActivityOctober 7, 2024 | benzinga.comVincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate UpdatesOctober 7, 2024 | globenewswire.comVincerx Pharma (NASDAQ:VINC) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comCompanies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite RiskyAugust 21, 2024 | finance.yahoo.comBuy Rating Affirmed for Vincerx Pharma Amid Positive Clinical Progress and Stable Financial OutlookAugust 14, 2024 | markets.businessinsider.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q2 2024August 9, 2024 | investorplace.comVincerx Pharma Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comVincerx Pharma GAAP EPS of -$0.58May 15, 2024 | msn.comVincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | finanznachrichten.deVINC Stock Earnings: Vincerx Pharma Misses EPS for Q1 2024May 14, 2024 | investorplace.comVincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comWhy Vincerx Pharma (VINC) Stock Is FallingApril 26, 2024 | msn.comVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and WarrantsApril 26, 2024 | globenewswire.comVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and WarrantsApril 25, 2024 | globenewswire.comVincerx Pharma, Inc. Common Stock (VINC)April 23, 2024 | nasdaq.comAgendia’s BluePrint Included in German Oncology Group GuidelinesApril 12, 2024 | finance.yahoo.comThe Rise of Zyn: The Oral Nicotine Product Going ViralApril 10, 2024 | finance.yahoo.comVincerx Pharma Inc (VINC) Gets a Buy from Leerink PartnersApril 10, 2024 | markets.businessinsider.comTrading was temporarily halted for "VINC" at 09:04 AM with a stated reason of "LULD pause."April 9, 2024 | marketbeat.comACOR, HUBC and DATS among pre-market losersApril 9, 2024 | msn.comVincerx in selloff after early-stage data for cancer therapyApril 9, 2024 | msn.comCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)Cantor Fitzgerald reissued an "overweight" rating on shares of Vincerx Pharma in a report on Tuesday.April 9, 2024 | marketbeat.comWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?April 9, 2024 | investorplace.comVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024April 8, 2024 | globenewswire.comFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Vincerx Pharma in a research report issued to clients and investors on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will postApril 4, 2024 | marketbeat.comQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink PartnrsVincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Leerink Partnrs increased their Q1 2024 earnings per share (EPS) estimates for Vincerx Pharma in a report issued on Sunday, March 31st. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.April 3, 2024 | marketbeat.comVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023April 2, 2024 | investorplace.comVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateApril 1, 2024 | finanznachrichten.deVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reissued an "overweight" rating on shares of Vincerx Pharma in a report on Monday.April 1, 2024 | marketbeat.comVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024April 1, 2024 | finance.yahoo.comVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close LookMarch 29, 2024 | finance.yahoo.comVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024March 29, 2024 | marketwatch.comVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateMarch 29, 2024 | globenewswire.comShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%Vincerx Pharma, Inc. (NASDAQ:VINC - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 863,700 shares, a growth of 95.2% from the February 29th total of 442,400 shares. Currently, 6.4% of the company's shares are sold short. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 0.8 days.March 28, 2024 | marketbeat.comVincerx Pharma (VINC) Set to Announce Earnings on TuesdayVincerx Pharma (NASDAQ:VINC) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.March 25, 2024 | marketbeat.comVincerx Pharma IncMarch 19, 2024 | edition.cnn.comWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 12, 2024 | benzinga.comLeerink Partnrs Comments on Vincerx Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for Vincerx Pharma in a research note issued on Tuesday, March 5th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.40) for the quartMarch 9, 2024 | marketbeat.comFY2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Reduced by Leerink PartnrsVincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Research analysts at Leerink Partnrs decreased their FY2024 earnings estimates for shares of Vincerx Pharma in a research report issued on Tuesday, March 5th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings ofMarch 8, 2024 | marketbeat.comBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug PipelineMarch 7, 2024 | markets.businessinsider.comVincerx Pharma, Inc. to Post Q1 2024 Earnings of ($0.40) Per Share, Leerink Partnrs Forecasts (NASDAQ:VINC)Vincerx Pharma, Inc. (NASDAQ:VINC - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Vincerx Pharma in a note issued to investors on Tuesday, March 5th. Leerink Partnrs analyst J. Chang forecasts that the company will earn ($0.40) pMarch 7, 2024 | marketbeat.comVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024March 5, 2024 | globenewswire.comVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekMarch 5, 2024 | finance.yahoo.comVincerx Pharma Inc Ordinary Shares VINCFebruary 22, 2024 | morningstar.com Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Missed Nvidia? Watch this ASAP (Ad)This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket. Click here and I’ll tell you everything you need to know. VINC Media Mentions By Week VINC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VINC News Sentiment▼0.300.55▲Average Medical News Sentiment VINC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VINC Articles This Week▼71▲VINC Articles Average Week Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PRPH News Today CLNN News Today PASG News Today CALC News Today OKYO News Today NXTC News Today LUMO News Today LEXX News Today LTRN News Today SRZN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VINC) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this BEFORE November 19th.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
